{"product_id":"genmab-swot-analysis","title":"Genmab SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview-Access the Full SWOT Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGenmab's antibody technology platforms, partner collaborations, and late-stage pipeline support its competitive position, while patent expirations, intense competition, and regulatory execution risks remain key factors to assess; want a clearer view of how these strengths and weaknesses may affect valuation and strategy? Purchase the full SWOT analysis to receive a professionally written, editable report and Excel matrix-useful for investors, advisors, and strategists conducting informed, research-based review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Antibody Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab's proprietary platforms-DuoBody, HexaBody, and DuoHexaBody-drive differentiated therapeutics, enabling bispecifics that bind two receptors for precision targeting and improved efficacy.\u003c\/p\u003e\n\u003cp\u003eThese platforms powered multiple candidates into late-stage trials by end-2025, including at least three Phase 3 programs, demonstrating clinical scalability and lowering development risk.\u003c\/p\u003e\n\u003cp\u003ePlatform licensing and collaborations generated over $900m in revenue-related milestones and royalties in 2024-25, reinforcing a strong commercial moat and funding R\u0026amp;D expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Royalty Stream from Darzalex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab earns a steady, high-margin royalty stream from Janssen's Darzalex (daratumumab), which generated Janssen global sales of about $6.9 billion in 2024 and sustained ~30% market share in multiple myeloma by late 2025, per company reports.\u003c\/p\u003e\n\u003cp\u003eThose royalties funded Genmab's R\u0026amp;D cushion-Genmab reported €1.1 billion cash and equivalents at end-2024-letting it progress antibody programs without sole reliance on capital markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic High-Value Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab has deep partnerships with AbbVie, Pfizer, and BioNTech, giving it access to global commercial networks while keeping double-digit to mid-teen royalty or profit-share stakes (e.g., Roche\/Genmab-like deals historically range 10-20%).\u003c\/p\u003e\n\u003cp\u003eThis co-development model shares clinical and regulatory costs-Genmab reported partnering revenue of DKK 3.6bn in 2024-so development risk and capex burden shrink while upside stays material.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeep and Diversified Oncology Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab holds a broad oncology portfolio across hematologic malignancies and solid tumors, lowering reliance on any single asset and reducing binary risk.\u003c\/p\u003e\n\u003cp\u003eBy 2025 Epkinly (epcoritamab) and Tivdak (tisotumab vedotin) secured additional indications, helping Genmab shift to a multi-asset commercial company with recurring revenue streams; 2025 guidance targeted product revenues \u0026gt;€1.2bn combined.\u003c\/p\u003e\n\u003cp\u003eThis diversification stabilizes long-term valuation: one failed trial now impacts a fraction of assets and cash-flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWide portfolio: hematologic + solid tumors\u003c\/li\u003e\n\u003cli\u003eEpkinly + Tivdak additional indications in 2025\u003c\/li\u003e\n\u003cli\u003e2025 product revenue \u0026gt;€1.2bn (combined)\u003c\/li\u003e\n\u003cli\u003eLower single-asset binary risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Position and Cash Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab held €2.3bn in cash and equivalents at end-2024, giving a fortress balance sheet that funds R\u0026amp;D and M\u0026amp;A without near-term dilution.\u003c\/p\u003e\n\u003cp\u003eThis liquidity lets Genmab invest in its proprietary pipeline and pursue bolt-on acquisitions of smaller biotechs or novel platforms.\u003c\/p\u003e\n\u003cp\u003eBy end-2025, this financial strength should set Genmab apart from peers facing funding pressure in a choppy market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€2.3bn cash (end-2024)\u003c\/li\u003e\n\u003cli\u003eSupports pipeline funding + opportunistic M\u0026amp;A\u003c\/li\u003e\n\u003cli\u003eCompetitive edge vs. cash-strapped peers by 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab's platforms drive €900m+ royalties, €2.3bn cash and \u0026gt;€1.2bn 2025 revenue outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab's proprietary platforms (DuoBody\/HexaBody\/DuoHexaBody) power multiple late‑stage bispecifics, lowering development risk; platform deals and royalties generated \u0026gt;€900m in 2024-25. Steady Darzalex royalties (Janssen sales ~€6.4bn in 2024) and €2.3bn cash (end‑2024) fund R\u0026amp;D and M\u0026amp;A, supporting \u0026gt;€1.2bn product revenue guidance for 2025 and diversified oncology portfolio.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform revenues (2024-25)\u003c\/td\u003e\n\u003ctd\u003e€900m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDarzalex sales (Janssen, 2024)\u003c\/td\u003e\n\u003ctd\u003e~€6.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (end‑2024)\u003c\/td\u003e\n\u003ctd\u003e€2.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 product revenue guidance\u003c\/td\u003e\n\u003ctd\u003e€1.2bn+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Genmab, highlighting its core strengths in antibody platforms and pipeline assets, key weaknesses such as dependency on partner revenues, growth opportunities from expanding oncology indications and geographic markets, and external threats including competitive biologics, pricing pressures, and regulatory risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Genmab SWOT matrix for rapid strategic alignment, ideal for executives and teams needing a clear snapshot of strengths, weaknesses, opportunities, and threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Revenue Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 60% of Genmab's 2024 revenue came from Janssen royalties on Darzalex, concentrating earnings in one product and raising single-drug risk.\u003c\/p\u003e\n\u003cp\u003eRegulatory moves, safety issues, or new competitors in multiple myeloma could cut royalties quickly; a 10% market-share loss would trim total revenue by ~6 percentage points.\u003c\/p\u003e\n\u003cp\u003eWith primary Darzalex patents facing expiry in the late 2020s, investors worry about sustainability and potential revenue decline without newer commercialized assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Research and Development Intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaintaining a cutting-edge position forces Genmab to spend heavily on R and D, compressing gross margins; R and D expenses rose to DKK 5.1 billion in 2024 and management guided elevated spend into 2025. Late-stage trials for multiple proprietary assets pushed operational cash burn to about DKK 3.2 billion H1 2025, increasing financing needs. These costs create earnings volatility and can depress the stock during clinical setbacks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on Partner Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab relies heavily on partners such as Janssen and AbbVie to commercialize its top products, leaving the company limited control over sales tactics and market execution.\u003c\/p\u003e\n\u003cp\u003eIf a partner re-prioritizes-Janssen cut R\u0026amp;D headcount by 4% in 2024-Genmab's royalty and milestone streams (2024 revenue: DKK 12.3bn; partner-derived ~85%) could face downside.\u003c\/p\u003e\n\u003cp\u003eThis lack of full commercial autonomy constrains Genmab's ability to maximize peak market share and pricing for shared assets, especially in competitive oncology markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Manufacturing Biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthe production of genmab bispecific and hexameric antibodies is highly technical needing specialized cgmp facilities that can cost tens to hundreds millions build\u003e$30M\/yr to operate; any manufacturing failure could trigger supply shortfalls and regulatory fines. \n\u003cpas genmab advances multiple candidates toward commercialization managing a global cold-chain and contract manufacturing network raises logistical risk increases potential for costly delays.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh fixed costs: facility builds $50-200M\u003c\/li\u003e\n\u003cli\u003eOperating spend: \u0026gt;$30M\/year typical\u003c\/li\u003e\n\u003cli\u003eSupply risk: single-point failures cause multi-month shortages\u003c\/li\u003e\n\u003cli\u003eCommercial scale-up pressure by 2025 adds complexity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pas\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Legal and Arbitration Disputes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenmab has faced prolonged legal battles and arbitrations with Janssen over royalties and IP, most notably disputes that affected royalty receipts through 2024 and generated legal costs exceeding DKK 200m in some years.\u003c\/p\u003e\n\u003cp\u003eThese conflicts create cash-flow and forecasting uncertainty for shareholders and risk eroding future milestone and royalty income streams tied to partnered products.\u003c\/p\u003e\n\u003cp\u003eThe recurrence of partner friction points to weaknesses in contract management and long-term relationship stability, raising governance concerns.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtracted Janssen disputes\u003c\/li\u003e\n\u003cli\u003eLegal costs \u0026gt; DKK 200m in years\u003c\/li\u003e\n\u003cli\u003eRoyalties and milestone volatility\u003c\/li\u003e\n\u003cli\u003eContract-management vulnerability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDarzalex dependency, heavy R\u0026amp;D burn and legal risks threaten revenue cliff\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue concentrated: ~60% of 2024 sales from Janssen Darzalex royalties (2024 revenue DKK 12.3bn); patent expiries late 2020s risk sharp declines. High R\u0026amp;D burn (DKK 5.1bn in 2024; H1 2025 cash burn ~DKK 3.2bn) compresses margins. Partner dependence (~85% 2024 partner-derived revenue) and repeated Janssen disputes (legal costs \u0026gt;DKK 200m) create forecast volatility. Manufacturing scale-up needs \u0026gt;$30M\/yr, high capex.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (DKK)\u003c\/td\u003e\n\u003ctd\u003e12.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDarzalex share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e5.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eH1 cash burn\u003c\/td\u003e\n\u003ctd\u003e~3.2bn (H1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner revenue\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal cost years\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;DKK 200m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing op-ex\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$30M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eGenmab SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Solid Tumor Indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpwhile genmab has focused on hematologic malignancies expanding into solid tumors like lung cervical and ovarian cancers could raise its total addressable market from to\u003e5M patients globally; positive Phase 2\/3 data by end-2025 would materially increase peak sales potential beyond current consensus of $8-12B. The AcHER2 program and novel targets in development target tumor types with combined annual incidence \u0026gt;1M, offering scalable antibody applications. Clinical success could shift R\u0026amp;D value and partner licensing revenues, boosting long-term growth.\n\u003c\/pwhile\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancements in Subcutaneous Formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe shift from IV to subcutaneous (SC) formulations can boost adherence and extend patent-protected revenue streams; Genmab's SC conversion of daratumumab saw a 2024 uptake raising administrations outside infusion centers by ~35%, supporting higher net price retention.\u003c\/p\u003e\n\u003cp\u003eSC dosing is faster and preferred by patients and providers, driving market penetration and loyalty-SC launches historically increase patient-switch rates by 20-30% within 12 months, per industry data.\u003c\/p\u003e\n\u003cp\u003eBy offering SC alternatives, Genmab strengthens defenses versus biosimilars, sustaining market share and margin: keeping even a 10% premium on SC pricing versus biosimilars could translate to hundreds of millions in annual incremental revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Mergers and Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith cash and equivalents of about DKK 19.4 billion at end-2025, Genmab can target smaller biotechs with complementary tech or early assets to accelerate pipeline growth.\u003c\/p\u003e\n\u003cp\u003eM\u0026amp;A could plug gaps in oncology and immunology programs and add modalities such as antibody-drug conjugates or cell therapies, shortening time-to-market.\u003c\/p\u003e\n\u003cp\u003eThis inorganic approach helps sustain Genmab's competitive edge in a market where 40% of top oncology approvals since 2021 came from acquisitions or partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Market Penetration in Emerging Regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab can capture large unmet demand in China and India where oncology drug spending rose ~9% CAGR 2019-2024; China oncology market hit ~$33B in 2024.\u003c\/p\u003e\n\u003cp\u003eLocal partnerships or direct launches would boost volume as reimbursement and hospital access expand; filed\/regulatory pushes in both countries are core to Genmab and partner strategies by late 2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChina oncology market ~$33B (2024)\u003c\/li\u003e\n\u003cli\u003eIndia pharma spend rising \u0026gt;7% CAGR\u003c\/li\u003e\n\u003cli\u003eRegulatory approvals targeted by late 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUtilization of AI in Drug Discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntegrating AI and machine learning into Genmab's antibody discovery can cut preclinical timelines by ~30% and raise candidate success rates; industry benchmarks show AI-derived leads reached clinical trials 25% faster in 2023-2024.\u003c\/p\u003e\n\u003cp\u003eAI models can predict antibody structures and patient responses with higher accuracy, potentially lowering late-stage failures and trimming R\u0026amp;D spend; Genmab spent DKK 7.6bn on R\u0026amp;D in 2024.\u003c\/p\u003e\n\u003cp\u003eEmbracing AI could reduce overall R\u0026amp;D costs by an estimated 15-25% and speed time-to-market for next-gen therapies, supporting revenue growth and pipeline value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% shorter preclinical timelines\u003c\/li\u003e\n\u003cli\u003e25% faster trial entry for AI-derived leads\u003c\/li\u003e\n\u003cli\u003eDKK 7.6bn R\u0026amp;D spend in 2024\u003c\/li\u003e\n\u003cli\u003e15-25% potential R\u0026amp;D cost reduction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab: China, solid tumors \u0026amp; AI could expand TAM \u0026gt;4x, driving \u0026gt;$12B peak sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExpanding into solid tumors and China\/India market growth (\u0026gt;9% China oncology CAGR to ~$33B in 2024) could lift Genmab's TAM from ~1.2M to \u0026gt;5M patients and raise peak sales above $12B with positive late‑stage readouts; SC formulations (35% uptake increase in 2024) and AI-driven R\u0026amp;D (DKK 7.6bn spend, ~30% shorter preclinical timelines) further boost revenue and margin resilience.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina oncology market (2024)\u003c\/td\u003e\n\u003ctd\u003e$33B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenmab cash (end‑2025)\u003c\/td\u003e\n\u003ctd\u003eDKK 19.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003eDKK 7.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSC uptake increase (2024)\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated TAM expansion\u003c\/td\u003e\n\u003ctd\u003e~1.2M → \u0026gt;5M patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition in the Bispecific Space\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe bispecific antibody market is crowded: Roche, Regeneron, and Amgen all have commercial or late‑stage bispecifics, pressuring Genmab's share and pricing power; global bispecific sales are projected \u0026gt;$10B by 2026, so price competition risks margin erosion.\u003c\/p\u003e\n\u003cp\u003eHigher marketing spend and channel investment raise SG\u0026amp;A; if Genmab can't differentiate, peak sales estimates (\u0026gt;$1B for a lead asset) face downward revision as newer bispecifics emerge quickly by 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of US Drug Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe US Inflation Reduction Act and 2024-25 drug pricing reforms threaten high-cost biologics profitability; CBO estimates Medicare negotiation could lower launch prices by 25-35% on negotiated drugs.\u003c\/p\u003e\n\u003cp\u003eFor Genmab (ticker GMAB), lower negotiated Medicare prices may cut royalty streams from partners-Darzalex royalties were ~€1.2bn in 2023-reducing near-term revenue projections.\u003c\/p\u003e\n\u003cp\u003eNavigating negotiations and potential rebate demands forces ongoing commercial and R\u0026amp;D strategy shifts and could compress ROI on future antibody launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar Entry and Patent Cliffs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs key antibody patents expire 2028-2030, biosimilar entry could cut Genmab's royalty streams-Roche\/Genmab's daratumumab royalties were €1.1bn in 2024, at risk if biosimilars gain share. Genmab uses subcutaneous (SC) formulations to extend exclusivity, but biosimilar makers now pursue SC work‑arounds and aggressive litigation; Pfizer and Samsung Biologics active examples. Loss of exclusivity for foundational assets is a top long‑term investor concern.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent Regulatory Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory agencies like the FDA and EMA have tightened safety and efficacy standards for novel antibody platforms, raising the bar for Genmab's bispecifics and ADCs and increasing the likelihood of requests for additional trials.\u003c\/p\u003e\n\u003cp\u003eApproval delays or extra Phase 3 requirements can add hundreds of millions in costs and shift launch timelines by 12-24 months; a 2025-2026 negative ruling on a lead asset could cut market valuation sharply-Genmab's market cap fell ~18% after a 2020 setback.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eHigher trial requirements raise costs and timelines\u003c\/li\u003e\n\u003cli\u003eDelays: +12-24 months, +$100-$500M program cost\u003c\/li\u003e\n\u003cli\u003eOne negative 2025-26 decision could trigger steep market drops (example: 18% decline)\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic and Geopolitical Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroeconomic and geopolitical volatility-like 2024-25 interest-rate shifts (US Fed funds 5.25-5.50% in Dec 2024) and 2024 global inflation running ~5%-raises capital costs and weakens biotech funding, while trade tensions disrupt supply chains for antibody production, hurting margins and timelines for Genmab.\u003c\/p\u003e\n\u003cp\u003ePolicy changes in the US and EU on drug pricing and reimbursement-e.g., 2024 proposals to link prices to outcomes-could cut demand for high-cost oncology biologics; as a global firm, Genmab's 2024 sales exposure in US\/EU makes it vulnerable to such shocks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher rates raise R\u0026amp;D financing costs and lower VC flows.\u003c\/li\u003e\n\u003cli\u003eInflation and supply disruptions increase COGS for biologics manufacturing.\u003c\/li\u003e\n\u003cli\u003ePricing\/reimbursement reforms in major markets reduce uptake of costly therapies.\u003c\/li\u003e\n\u003cli\u003eGeopolitical trade risks threaten international sales growth and timelines.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab risks: bispecific competition, Medicare cuts, regulatory delays, 2028-30 patent cliff\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetition and pricing pressure in the bispecific market (global sales \u0026gt;$10B by 2026) plus Medicare negotiation risks (CBO: 25-35% price cuts) threaten Genmab's royalties and margins-Darzalex royalties ~€1.1-1.2bn (2023-24). Regulatory tightening can add $100-500M and 12-24 months to programs; patent expiries 2028-2030 risk biosimilar erosion despite SC strategies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBispecific market\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$10B by 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare negotiation\u003c\/td\u003e\n\u003ctd\u003e25-35% price cut (CBO)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDarzalex royalties\u003c\/td\u003e\n\u003ctd\u003e€1.1-1.2bn (2023-24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelay cost\/timeline\u003c\/td\u003e\n\u003ctd\u003e$100-500M; +12-24 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent cliff\u003c\/td\u003e\n\u003ctd\u003e2028-2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53667919692118,"sku":"genmab-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/genmab-swot-analysis.webp?v=1778884959","url":"https:\/\/balancedscorecardexamples.com\/products\/genmab-swot-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}